Evercore ISI upgraded Seagen to Outperform from In Line with a price target of $175, up from $140. There are "so many growth drivers firing" at Seagen and positive catalysts ahead, said the analyst, who adds that while the firm would "prefer a better entry point, we don’t think we’ll get it."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGEN:
- Seagen upgraded to Strong Buy from Outperform at Raymond James
- Seagen sees FY23 revenue $2.14B-$2.24B, consensus $2.3B
- Seagen reports Q4 EPS (80c), consensus ($1.04)
- Cellectar Biosciences hires Shustov as new Senior Vice President, Medical
- Seagen treatment of esophageal cancer granted orphan designation